Codrituzumab/GC33/RO5137382 (GC33) is a humanized monoclonal antibody that binds to human GPC-3 expressing HCC cell line with an in vivo cytotoxic activity against tumor cells. This evidence concerns the gene GPC3 and hepatocellular carcinoma.